Personalized Biopsy Schedules Using an Interval‐Censored Cause‐Specific Joint Model
Statistics in Medicine · 2025
DOI: 10.1002/sim.70134 ↗At a glance
Journal article in Statistics in Medicine, 2025. Written by Zhenwei Yang and 4 co-authors. Institution: Department of Biostatistics, Erasmus Medical Center Rotterdam, South Holland, the Netherlands. Major MEDLINE topics: Prostatic Neoplasms, Precision Medicine, Models, Statistical. Cited 1 times so far (Crossref); 39 references. The full text is freely available (open access, CC BY 4.0). Funded by: NCI NIH HHS, NIH HHS, National Institutes of Health.
Abstract (original language)
Active surveillance (AS), where biopsies are conducted to detect cancer progression, has been acknowledged as an efficient way to reduce the overtreatment of prostate cancer. Most AS cohorts use fixed biopsy schedules for all patients. However, the ideal test frequency remains unknown, and the routine use of such invasive tests burdens the patients. An emerging idea is to generate personalized biopsy schedules based on each patient's progression‐specific risk. To achieve that, we propose the interval‐censored cause‐specific joint model (ICJM), which models the impact of longitudinal biomarkers on cancer progression while considering the competing event of early treatment initiation. The underlying likelihood function incorporates the interval‐censoring of cancer progression, the competing risk of treatment, and the uncertainty about whether cancer progression occurred since the last biopsy in patients that are right‐censored or experience the competing event. The model can produce patient‐specific risk profiles up to a horizon time. If the risk exceeds a certain threshold, a biopsy is conducted. The optimal threshold can be chosen by balancing two indicators of the biopsy schedules: The expected number of biopsies and the expected delay in detection of cancer progression. A simulation study showed that our personalized schedules could considerably reduce the number of biopsies per patient by 41%–52% compared to the fixed schedules, though at the cost of a slightly longer detection delay.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Biostatistics, Erasmus Medical Center Rotterdam, South Holland, the Netherlands.
- Department of Epidemiology, Erasmus Medical Center Rotterdam, South Holland, the Netherlands.
- Department of Public Health, Erasmus Medical Center Rotterdam, South Holland, the Netherlands.
- Cancer Prevention Program, Fred Hutchinson Cancer Center, Seattle, WA, USA.
- Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
ORCID profiles: Zhenwei Yang, Dimitris Rizopoulos, Nicole S Erler
Funding
- NCI NIH HHS
- NIH HHS
- National Institutes of Health
Cite
APA
Yang, Z., Rizopoulos, D., Heijnsdijk, E. A. M., Newcomb, L. F., & Erler, N. S. (2025). Personalized Biopsy Schedules Using an Interval‐Censored Cause‐Specific Joint Model. Statistics in Medicine. https://doi.org/10.1002/sim.70134
Vancouver
Yang Z, Rizopoulos D, Heijnsdijk EAM, Newcomb LF, Erler NS. Personalized Biopsy Schedules Using an Interval‐Censored Cause‐Specific Joint Model. Statistics in Medicine. 2025. doi:10.1002/sim.70134
BibTeX
@article{Yang2025,
author = {Yang, Zhenwei and Rizopoulos, Dimitris and Heijnsdijk, Eveline A M and Newcomb, Lisa F and Erler, Nicole S},
title = {Personalized Biopsy Schedules Using an Interval‐Censored Cause‐Specific Joint Model},
journal = {Statistics in Medicine},
year = {2025},
doi = {10.1002/sim.70134}
}
EUVIMED